CathWorks Series B · $16M raised · (2017)

CathWorks develops a drug-free, wire-free system that combines artificial intelligence and computational science to obtain physiologic information from routine angiograms. Their FFRangio® System provides physicians with a quick and reliable intraprocedural physiologic assessment for the entire coronary tree, enhancing decision-making for treating Coronary Artery Disease. This technology serves interventional cardiologists and their patients by offering a less invasive and more comprehensive approach to assessing heart conditions.